Online citations, reference lists, and bibliographies.
← Back to Search

Three-dimensional Evaluation Of Chemotherapy Response In Malignant Pleural Mesothelioma.

G. Ak, M. Metintas, S. Metintaş, H. Yildirim, R. Ozkan, H. Ozden
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
OBJECTIVES Measurement of tumor response to chemotherapy in malignant pleural mesothelioma (MPM) is problematic because of non-spherical tumor growth patterns and difficulty in choosing target lesion. In this study, we aimed to determine the effectiveness of tumor volume measurement for evaluating chemotherapy response. METHODS Fifty-seven MPM patients were included. Chemotherapy responses were evaluated by computed tomography (CT) using volumetric method, World Health Organization (WHO), and modified Response Evaluation Criteria in Solid Tumor (RECIST). The tumor volume was measured using the Cavalieri principle of stereological approaches. RESULTS According to the volumetric method, median survival was 10.0 months for progressive disease (PD), 14.0 months for stable disease (SD) and 16.0 months for objective response (OR). According to the WHO method, median survival was 11.3, 14.0, and 13.0 months, respectively. For modified RECIST, median survival was 10.0, 14.0, and 14.0 months, respectively. The correspondence between the WHO and modified RECIST methods was substantial (K=0.66), as was that between the volumetric and WHO methods (K=0.64); however the correspondence between the volumetric and modified RECIST methods was only moderate (K=0.52). CONCLUSIONS The most suitable chemotherapy response measurement technique is the volumetric method because of non-spherical tumor growth patterns in MPM. However, larger studies should be performed to better establish the suitability of this method. We recommend our method for determining the chemotherapy response in mesothelioma cases. However, modified RECIST criteria can also be applied due to favourable prediction of survival, ease of application, and moderate correspondence with the volumetric method.
This paper references
10.1016/J.LUNGCAN.2004.04.020
Chemotherapy for malignant pleural mesothelioma: past results and recent developments.
S. Tomek (2004)
10.1118/1.1688211
Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques.
S. Armato (2004)
10.1016/S0169-5002(03)00292-7
Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma.
R. V. van Klaveren (2004)
10.1016/S0720-048X(01)00426-0
Computed tomography features in malignant pleural mesothelioma and other commonly seen pleural diseases.
M. Metintas (2002)
10.1248/JHS.53.23
Relationship between tumorsize of malignant pleural mesothelioma and its response to chemotherapy
H. Ozden (2007)
10.1016/J.ACRA.2005.05.021
Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans.
S. Armato (2005)
10.1111/j.1365-2818.1993.tb03381.x
Unbiased estimation of human body composition by the Cavalieri method using magnetic resonance imaging
N. Roberts (1993)
10.1016/J.EJRAD.2005.07.006
Assessment of the optimum section thickness for the estimation of liver volume using magnetic resonance images: a stereological gold standard study.
B. Sahin (2006)
10.1093/JNCI/91.6.523
Measuring response in solid tumors: unidimensional versus bidimensional measurement.
K. James (1999)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/J.LUNGCAN.2005.12.013
Modeling of mesothelioma growth demonstrates weaknesses of current response criteria.
G. Oxnard (2006)
10.1148/RADIOL.2252011604
CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations.
S. Prasad (2002)
10.1093/jnci/92.3.205
New Guidelines to Evaluate the Response to Treatment in Solid Tumors.
P. Therasse (2000)
10.1016/S0720-048X(03)00077-9
Rapid estimation of the vertebral body volume: a combination of the Cavalieri principle and computed tomography images.
E. Odacı (2003)
10.1016/S0169-5002(07)70157-5
81 Development of a computer method for volumetric response assessment in mesothelioma
B. Zhao (2006)
10.1016/J.LUNGCAN.2006.11.005
A retrospective analysis of malignant pleural mesothelioma patients treated either with chemotherapy or best supportive care between 1990 and 2005 A single institution experience.
M. Metintas (2007)
10.1111/j.1365-2818.1987.tb02837.x
The efficiency of systematic sampling in stereology and its prediction *
H. Gundersen (1987)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1016/j.neuroimage.2005.01.005
Assessment of in vivo MR imaging compared to physical sections in vitro—A quantitative study of brain volumes using stereology
J. Jelsing (2005)
10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
Reporting results of cancer treatment
A. Miller (1981)
10.1378/CHEST.122.6.2224
Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area.
S. Metintaş (2002)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1200/JCO.2006.06.8999
Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [18F]Fluorodeoxyglucose
G. Ceresoli (2006)
10.1016/J.LUNGCAN.2003.07.005
Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases.
F. Monetti (2004)



This paper is referenced by
10.1016/j.jtho.2018.02.021
State of the Art : Advances in Malignant Pleural Mesothelioma in 2017
Amanda J McCambridge (2018)
10.1109/IASP.2011.6109016
Quantitative stereological analysis of confocal laser scanning microscopic images of cells
Na Hu (2011)
10.1097/JTO.0b013e318208c83d
A Practical Guide of the Southwest Oncology Group to Measure Malignant Pleural Mesothelioma Tumors by RECIST and Modified RECIST Criteria
A. Tsao (2011)
10.1007/s00330-018-5887-z
Correlation of patient survival with clinical tumor measurements in malignant pleural mesothelioma
Feng Li (2018)
Imaging biomarkers of the tumour microenvironment to assess early response in patients treated with anti-angiogenic therapy
Laura Horsley (2015)
Computer-assisted volumetric tumour assessment for the evaluation of patient response in malignant pleural mesothelioma
J. A. Schnabel (2011)
10.1097/JTO.0b013e318229a41e
Implications of Delayed Initiation of Radiotherapy: Accelerated Repopulation after Induction Chemotherapy for Stage III Non-small Cell Lung Cancer
C. P. Chen (2011)
10.1136/thoraxjnl-2017-211321
British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma
I. Woolhouse (2018)
10.1016/j.jtho.2018.02.021
Progress in the Management of Malignant Pleural Mesothelioma in 2017
Amanda J McCambridge (2018)
10.1002/bjs.9872
Portal vein embolization and its effect on tumour progression for colorectal cancer liver metastases
E. Simoneau (2015)
10.1097/JTO.0b013e31826915f1
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
V. Rusch (2012)
10.21037/atm.2017.05.23
Volumetric assessment in malignant pleural mesothelioma.
D. Murphy (2017)
10.1183/09031936.00146110
Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?
T. Frauenfelder (2011)
10.3892/etm.2017.5471
Rivaroxaban for the treatment of venous thromboembolism in patients with nephrotic syndrome and low AT-III: A pilot study
L. Zhang (2018)
10.1097/JTO.0b013e3182199be2
Assessment of Objective Responses Using Volumetric Evaluation in Advanced Thymic Malignancies and Metastatic Non-small Cell Lung Cancer
Jeremy Force (2011)
10.1016/j.ejrad.2012.05.018
Size determination and response assessment of liver metastases with computed tomography--comparison of RECIST and volumetric algorithms.
J. H. Rothe (2013)
10.1016/j.jtcvs.2018.09.106
Pleural thickness after neoadjuvant chemotherapy is a prognostic factor in malignant pleural mesothelioma
M. Hashimoto (2019)
10.1007/s13665-012-0010-4
Emerging therapies for malignant pleural mesothelioma
J. Quispel-Janssen (2012)
10.1007/s11548-016-1511-3
Computer-aided volumetric assessment of malignant pleural mesothelioma on CT using a random walk-based method
Mitchell Chen (2016)
10.1016/j.lungcan.2015.08.012
Response evaluation in mesothelioma: Beyond RECIST.
Lin Cheng (2015)
10.3978/j.issn.2225-319X.2012.11.10
Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database.
V. Rusch (2012)
10.1016/j.athoracsur.2016.06.069
A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma.
V. Rusch (2016)
10.1007/s10585-017-9855-9
Next generation sequencing of progressive colorectal liver metastases after portal vein embolization
E. Simoneau (2017)
10.1038/bjc.2015.62
The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication
C. Hooper (2015)
10.1016/J.CLLC.2019.06.019
The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma.
C. Proto (2019)
Semantic Scholar Logo Some data provided by SemanticScholar